Some cookies are essential to the running of the website, while others (analytics) help us to make improvements. We also incorporate functionality from other websites, such as video, social media feeds and ReachDeck (text-to-speech and translations services) which may set cookies. More on how we use cookies
This website uses text-to-speech software called ReachDeck to read and / or translate its content. To use ReachDeck, you must allow ReachDeck cookies; the ReachDeck icon will then appear at the bottom right of your screen.
You can find out more about how ReachDeck uses cookies or change your cookie preferences at any time by going to our cookies page.
Allow ReachDeck cookies Do not use ReachDeck
Please find service updates and current visiting rules in our COVID-19 section.
This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.
The MHRA have a definition of a serious breach of GCP: a 'serious breach' is a breach that is likely to affect to a significant degree:
In the event that a serious breach is suspected, the OUH R&D Department must be contacted so that an investigation of the concern can be undertaken as a matter of urgency.
The Clinical Trials regulations state that the Sponsor is required to report serious breaches to the REC, and MHRA (where applicable) within seven days of becoming aware of the breach.
OUH R&D can provide information on what should, or should not, be classified as a serious breach and on the practical arrangements for notifications.
The Regulations define 'serious breaches' as any serious breach of: